Alzheimer; News from the web:
Low-dose ionizing radiation may be a promising, although possibly controversial, therapy for Alzheimer’s disease, according to the researchers behind a small new pilot study.
Read all about it HERE
Alzheimer; News from the web:
Low-dose ionizing radiation may be a promising, although possibly controversial, therapy for Alzheimer’s disease, according to the researchers behind a small new pilot study.
Read all about it HERE
Alzheimer; News from the web:
What if we think of Alzheimer’s not as one disease, but three separate ones, with overlapping symptoms? Researchers behind a new study say Alzheimer’s encapsulates three distinct molecular conditions, and that a better understanding of each could be a lifeline for failed Alzheimer’s treatment efforts and future research.
Read all about it HERE
Alzheimer; News from the web:
Exercising regularly has many health benefits, but did you know aerobic exercise could also benefit older adults living with Alzheimer’s dementia?
https://www.timesnownews.com/
Read all about it HERE
Alzheimer; News from the web:
In 2018, a research group led by David Holtzman, M.D., at Washington University in St. Louis developed an antibody drug in collaboration with Denali Therapeutics that showed promise as a potential Alzheimer’s disease therapy. Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab.
Read all about it HERE
Alzheimer; News from the web:
Twenty Veterans with Alzheimer’s disease and apathy took part in a pilot study. Half received repetitive transcranial magnetic stimulation (rTMS), a type of brain stimulation. The others received sham stimulation, basically a placebo.
Through patient and caregiver interviews, the VA team documented “significantly greater improvement” in apathy levels in those who received brain stimulation compared with the control group. The positive effects continued up to three months.
Besides improvements in apathy, the researchers also noted “significantly greater improvement” in memory, attention, and cognition in the rTMS patients compared with the sham treatment group.
Read all about it HERE
Alzheimer; News from the web:
Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.
The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked. The experts warned of multiple “red flags” with the data, which did not initially show any benefit until another analysis with later results.
Read all about it HERE